Assessment of antitumor activity and acute peripheral neuropathy of 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016)

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 3005-3012

  Ueno, Takayoshi ^a   Endo, Kazuhira ^a   Hori, Kiyomi ^a   Ozaki, Noriyuki ^a   Tsuji, Akira ^a   Kondo, Satoru ^a   Wakisaka, Naohiro ^a   Murono, Shigeyuki ^a   Kataoka, Kazunori ^b,c   Kato, Yasuki ^d   Yoshizaki, Tomokazu ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NanoCarrier Co Ltd   (Japan)

Author keywords

Carcinoma; Chemotherapy; Drug delivery system; Oxaliplatin

Indexed keywords

NC 4016; OXALIPLATIN; PLATINUM 1,2 DIAMINOCYCLOHEXANE; UNCLASSIFIED DRUG; ((1R,2R)-1,2-DIAMINOCYCLOHEXANE)PLATINUM(II); ANTINEOPLASTIC AGENT; MICELLE; NANOCAPSULE; PLATINUM COMPLEX;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOMA CELL LINE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HYPERALGESIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MICELLE; MOUSE; NONHUMAN; PERIPHERAL NEUROPATHY; RAT; SINGLE DRUG DOSE; ANIMAL; C57BL MOUSE; CELL SURVIVAL; CHEMICALLY INDUCED; CHEMISTRY; DIFFUSION; DOSE RESPONSE; DRUG EFFECTS; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DIFFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MICE, INBRED C57BL; MICE, NUDE; MICELLES; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84902983923     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S60564     Document Type: Article

References (29)

1. Kidani Y, Noji M, Tashiro T. Antitumor activity of platinum (II) complexes of 1,2-diamino-cyclohexane isomers. Gann. 1980;71(5):637-643.
2. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol. 1996;52(12):1855-1865.
3. Tashiro T, Kawada Y, Sakurai Y, Kidani Y. Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data. Biomed Pharmacother. 1989;43(4):251-260.
4. Degardin M, Cappelaere P, Krakowski I, Fargeot P, Cupissol D, Brienza S. Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol. 1996;32B(4):278-279.
5. Raguse JD, Gath HJ, Oettle H, Bier J. Oxaliplatin, folinic acid and 5-fluorouracil (OFF) in patients with recurrent advanced head and neck cancer: a phase II feasibility study. Oral Oncol. 2006;42(6):614-618.
6. Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol. 2002;42(3):317-325.
7. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol. 2002;29(5 Suppl 15):21-33.
8. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003;30(4 Suppl 15):5-13.
9. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771-782.
10. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-160.
11. Nishiyama N, Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther. 2006;112(3):630-648.
12. Nishiyama N, Okazaki S, Cabral H, et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res. 2003;63(24):8977-8983.
13. Cabral H, Nishiyama N, Okazaki S, Koyama H, Kataoka K. Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum (II) (DACHPt)-loaded polymeric micelles. J Control Release. 2005;101(1-3):223-232.
14. Endo K, Ueno T, Kondo S, et al. Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma. Cancer Sci. 2013;104(3):369-374.
15. Kidani Y, Inagaki K, Iigo M, Hoshi A, Kuretani K. Antitumor activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form. J Med Chem. 1978;21(12):1315-1318.
16. Fujii R, Mutoh M, Niwa K, et al. Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn J Cancer Res. 1994;85(4):426-433.
17. Nathan CO, Amirghahari N, Rong X, et al. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res. 2007;67(5):2160-2168.
18. Carlsson G, Gullberg B, Hafström L. Estimation of liver tumor volume using different formulas-an experimental study in rats. J Cancer Res Clin Oncol. 1983;105(1):20-23.
19. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain. 2004;109(1-2):150-161.
20. Cabral H, Nishiyama N, Kataoka K. Optimization of (1,2-diamino-cyclohexane) platinum (II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity. J Control Release. 2007;121(3):146-155.
21. Yamamoto Y, Hyodo I, Takigahira M, et al. Effect of combined treatment with the epirubicin-incorporating micelles (NC-6300) and 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016) on a human gastric cancer model. Int J Cancer. 2014;135(1):214-223.
22. Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol. 1998;25(2 Suppl 5):S13-S22.
23. Pasetto LM, D'Andrea MR, Rossi E, Monfardini S. Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol. 2006;59(2):159-168.
24. Ling B, Authier N, Balayssac D, Eschalier A, Coudore F. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain. 2007;128(3):225-234.
25. Sakurai M, Egashira N, Kawashiri T, Yano T, Ikesue H, Oishi R. Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Pain. 2009;147(1-3):165-174.
26. Kawashiri T, Egashira N, Watanabe H, et al. Prevention of oxaliplatin-induced mechanical allodynia and neurodegeneration by neurotropin in the rat model. Eur J Pain. 2011;15(4):344-350.
27. Norcini M, Vivoli E, Galeotti N, Bianchi E, Bartolini A, Ghelardini C. Supraspinal role of protein kinase C in oxaliplatin-induced neuropathy in rat. Pain. 2009;146(1-2):141-147.
28. Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004;10(12 Pt 1):4055-4061.
29. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol. 2001;85(5):2293-2297.